A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and
schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for
the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules
of (tal+tec+dara) the treatment combinations to be pursued in Phase 2.